ClinicalTrials.gg
RecruitingNCT05114096SNACSUpdated Jan 7, 2026

Single Dose of Antenatal Corticosteroids for Pregnancies at Risk of Preterm Delivery (SNACS)

A Phase 4 interventional study of Celestone + placebo and Celestone + Celestone in Preterm Birth, Premature Birth and Complication of Prematurity, sponsored by McMaster University. Recruiting at 25 sites in Canada. Open to female participants aged 18 Years to 55 Years. Per ClinicalTrials.gov, last updated 2026-01-07.

Sponsored by McMaster University · Phase 4, Interventional, and Other

How we know

From the registry’s dates

  • Started Jul 2023; still recruiting 3 years 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
3,254
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 139 studies in Premature Birth with a site in Canada — 26 open to participants now, 34 under way, 2 of them phase 3. Premature Birth · Canada.

Planned enrollment
2nd of 106
3,254 · median 80
Started
2023
with 6 others
Phase 4
5 of 139
2 open now
Primary completion
2026-12
later than 18 of 33 live
Registered
111th of 139
by date
Lead sponsor
6 of 139
McMaster University

Among the 139 studies in Premature Birth with a site in Canada, this one is the 2nd largest by planned enrollment of the 106 interventional ones that give a count, is one of 7 that started in 2023, is one of 5 in phase 4, reaches primary completion later than 18 of the 33 other live ones, and was the 111th registered.

Premature Birth

2,557 studies on the registry are indexed under Premature Birth; 504 are open to participants now.

Browse Premature Birth studies →

Open to participants now

26 of the 139 studies in Premature Birth with a site in Canada are open now. Recruiting first, the newest first:

20 more — sign in →

All 26 open studies →

A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →

Who these studies take

Of the 318 Premature Birth studies recruiting now, 88 (28%) set no upper age limit and 226 (71%) stop at 75 or younger; 243 take children under 18; 104 take healthy volunteers.

This study: 18 Years to 55 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 139 studies in Premature Birth with a site in Canada, or all of them as a file.
02

Study summary

Antenatal corticosteroids (ACS) reduce the risks of neonatal death and morbidities in preterm infants, such as respiratory distress syndrome.

The standard of care for pregnant people at risk of preterm birth includes 2 doses of Celestone (for a total of 24 mg in Canada, or 22.8 mg in Australia) to accelerate fetal lung maturity.

The investigators plan to conduct a randomized controlled trial to determine whether half the usual dose (12 mg in Canada, or 11.4 mg in Australia) of Celestone is non-inferior to the standard double doses.

Read the detailed description

Preterm infants are at risk of mortality and morbidity. Antenatal corticosteroids (ACS) reduce the risks of neonatal death and morbidities, such as respiratory distress syndrome.

The standard of care for pregnant people at risk of preterm birth includes 2 doses of Celestone to accelerate fetal lung maturity (total 24 mg in Canada, 22.8 mg in Australia). There are no published clinical trial data on the benefits or risks of a single dose of antenatal corticosteroid vs. standard double doses (Ninan et al JOGC 2020).

Pregnant people at 22 weeks and 0 days to \< 34 weeks and 6 days' gestation at risk of preterm birth with a singleton or twin gestation who have received the first dose of Celestone and consented to the trial will be randomized to receive approximately 24 hours later either an experimental placebo injection (of normal saline) or the standard double dose of Celestone to determine whether the intervention is non-inferior for the primary outcome of a composite of perinatal mortality or substantial morbidity.

Please note: Based on Health Canada's' guidance the study phase is 'Other: Off-Label use'. However, on the clincaltrial.gov record, 'Phase 4' is selected as this is the most relevant phase and there is no option to select 'Other'.

Please note: McMaster University, Canada is the Canadian Regulatory Sponsor and Overall Sponsor, and the University of Adelaide Australia is the Australian Sponsor.

03

Conditions studied

  • Preterm Birth
  • Premature Birth
  • Complication of Prematurity
  • Obstetric Labor, Premature
  • Pregnancy Complications

Keywords

  • Premature birth
  • Preterm birth
  • Obstetric labour
  • Betamethasone
  • Betamethasone Valerate
  • Betamethasone-17,21-dipropionate
  • Betamethasone benzoate
  • Betamethasone sodium phosphate
  • Anti-Inflammatory Agents
  • Glucocorticoids
  • Hormones
  • Hormones, Hormone Substitutes and Hormone Antagonists
  • Physiological Effect of Drugs
  • Anti-Asthmatic Agents
  • Respiratory System Agents
04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Pregnant people, aged 18 to 55 years old, at risk of preterm birth with a singleton or twins between 22 weeks and 0 days and \<34 weeks and 6 days gestation who have received only a single dose of Celestone within 24 hours
  2. Capable of giving informed, written consent.

Exclusion criteria

Exclusion Criteria:

  1. to
  2. Systemic corticosteroids for medical conditions during the pregnancy (e.g. lupus, severe asthma, Covid, etc).
  3. Previous participation in this trial (in a previous pregnancy)
  4. Known severe/life-threatening fetal or pregnant patient condition (e.g. fetal congenital/chromosomal abnormality)
  5. Demise of one or more fetuses after 14 weeks and 0 days
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 4
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
3,254 participants (estimated)

Study arms

  • Experimental
    Single-Dose Celestone

    Having already received the first dose of Celestone as part of eligibility criteria, participants randomized to the experimental "Single-Dose" arm will receive a similar appearing placebo injection.

    Drug: Celestone + placebo

  • Active comparator
    Double-Dose Celestone

    Having already received the first dose of Celestone as part of eligibility criteria, participants randomized to the "Double-Dose" arm will receive the standard 2nd dose of Celestone injected intramuscularly (i.e. they will receive the standard double-dose regimen).

    Drug: Celestone + Celestone

Interventions

  • DrugCelestone + placebo

    After the first intramuscular injection of Celestone, participants randomized to the "Placebo Comparator" group will receive 1 intramuscular injection of placebo.

  • DrugCelestone + Celestone

    Drug page: BetamethasoneStudies of BetamethasoneBetamethasone pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    After the first intramuscular injection of Celestone, participants randomized to the "Active Comparator" group will receive 1 intramuscular injection of Celestone.

06

What researchers measure

Primary outcomes

  1. Perinatal Mortality or Substantial Neonatal Morbidity

    Fetal death post-randomization or in hospital neonatal death OR =\> 1 of respiratory morbidity (requiring surfactant \<=48 hrs of life), severe intraventricular hemorrhage (distending/beyond the ventricles, i.e. Grade 3 or 4), or severe bowel problem (necrotizing enterocolitis, Stage 2 or 3)

    Time frame: approximately 1 month

Secondary outcomes

  1. Death or neurosensory/developmental impairment at 24 months

    Death or neurosensory/developmental impairment at 24 months (+/- 6 months; accounting for gestation at birth), mood (anxiety/depression), behavior (aggression), etc as assessed by: 1. Ages and Stages Questionnaire-3 (ASQ) 2. Child Behavior Checklist: 4 subscales 3. Physician diagnosis of cerebral palsy (parent report).

    Time frame: approximately 24 months

Other outcomes

  1. Number of babies who received intubation and duration of invasive mechanical ventilation

    Number of babies who received intubation and duration of invasive mechanical ventilation

    Time frame: approximately up to first 6 months of life

  2. Number of babies who received, and duration of, supplemental oxygen (after resuscitation) and other ventilatory support

    Number of babies who received, and duration of, supplemental oxygen (after resuscitation) and other ventilatory support

    Time frame: approximately up to first 6 months of life

  3. Number of babies with respiratory distress after the initial resuscitation/stabilization and main cause

    Number of babies with respiratory distress after the initial resuscitation/stabilization and main cause (such as respiratory distress syndrome, pneumothorax/pneumomediastinum, pneumonia, transient tachypnea of the newborn, meconium aspiration syndrome, persistent pulmonary hypertension of the newborn)

    Time frame: approximately 1 month

  4. Number of babies with Respiratory distress after the initial resuscitation/stabilization and main cause

    Respiratory distress after the initial resuscitation/stabilization and main cause (such as respiratory distress syndrome, pneumothorax/pneumomediastinum, pneumonia, transient tachypnea of the newborn, meconium aspiration syndrome, persistent pulmonary hypertension of the newborn),

    Time frame: approximately at birth

  5. Number of babies with hypoglycemia

    Number of babies with hypoglycemia (low plasma glucose \< 2.6 mmol/L between 30 minutes and 48 hours of life)

    Time frame: 48 hours

  6. Number of babies with neonatal sepsis

    Number of babies with neonatal sepsis within 7 days of birth, defined as a positive (bacterial, viral or fungal): blood culture or cerebrospinal fluid culture (or gram stain) or urine culture by sterile collection.

    Time frame: 7 days

  7. Number of babies with severe retinopathy of prematurity needing treatment

    Number of babies with severe retinopathy of prematurity defined as requiring vascular endothelial growth factor (VEGF) or laser or cryotherapy per the local guidelines

    Time frame: approximately first few months of life

  8. Number of babies with patent ductus arteriosus (PDA) needing a closure procedure (surgery or device)

    Number of babies with patent ductus arteriosus (PDA) needing a closure procedure (surgery or device)

    Time frame: up to 12 weeks after birth

  9. Anthropometry at birth and at 24 months corrected age

    Weight (in grams), length (in centimeters), and head circumference (in centimeters) for birth week as ACS can impact growth

    Time frame: at birth and at 24 months corrected age

  10. Number of babies with severe late brain injury

    Periventricular leukomalacia \[PVL\], i.e. cystic changes in white matter or porencephalic cysts or white matter changes diagnosed by ultrasound or MRI.

    Time frame: up to 20 weeks postnatal

  11. Number of babies with chronic lung disease

    Late respiratory morbidity, bronchopulmonary dysplasia (BPD), defined as requiring respiratory support or supplemental oxygen \> 36 completed weeks' corrected gestation.

    Time frame: approximately up to first 6 months of life

  12. Apgar score and cord blood pH

    Apgar score (at 1 and 5 min) and lowest cord blood pH, regardless of whether arterial or venous.

    Time frame: approximately at birth

  13. Length of stay in special care or an intensive care setting

    Length of stay in an intensive care setting such as the neonatal intensive care unit (NICU).

    Time frame: approximately up to first 6 months of life

  14. Use of postnatal corticosteroids

    Use of systemic (intravenous or oral) postnatal corticosteroids and type (e.g. hydrocortisone, dexamethasone).

    Time frame: up to 20 weeks postnatal

  15. Number of babies with longterm health care outcomes

    Number of babies with reported longterm health care outcomes after initial hospital, such as hospitalizations, and other health care use.

    Time frame: approximately 5 -10 years

  16. Number of babies with longterm education outcomes

    Number of babies with reported longterm education or non-health data outcomes, collected through database linkage where possible.

    Time frame: approximately 5 -10 years

  17. Number of participants with fetal death post-randomization or in hospital neonatal death OR => 1 of respiratory morbidity, severe intraventricular hemorrhage , or severe bowel problem

    Fetal death post-randomization or in hospital neonatal death OR =\> 1 of respiratory morbidity (requiring surfactant \<=48 hrs of life), severe intraventricular hemorrhage (distending/beyond the ventricles, i.e. Grade 3 or 4), or severe bowel problem (necrotizing enterocolitis, Stage 2 or 3)

    Time frame: approximately 1 month

07

Study locations

16 of 25 sites recruiting
  • University of Calgary, Cumming School of Medicine
    Calgary, Alberta, Canada
    Recruiting
  • Alberta Health Services; University of Alberta
    Edmonton, Alberta, Canada
    Recruiting
  • Royal Columbian Hospital
    New Westminster, British Columbia, Canada
    Not yet recruiting
  • Fraser Health, University of British Columbia; Jim Pattison Outpatient Care and Surgery Centre
    Surrey, British Columbia, Canada
    Not yet recruiting
  • University of British Columbia; BC Women's Hospital
    Vancouver, British Columbia, Canada
    Not yet recruiting
  • Victoria General Hospital
    Victoria, British Columbia, Canada
    Not yet recruiting
  • University of Manitoba, Health Sciences Centre
    Winnipeg, Manitoba, Canada
    Not yet recruiting
  • University of Manitoba; St. Boniface General Hospital
    Winnipeg, Manitoba, Canada
    Not yet recruiting
  • Dr. Everett Chalmers Regional Hospital
    Fredericton, New Brunswick, Canada
    Recruiting
  • The Moncton Hospital, Horizon Health Network
    Moncton, New Brunswick, Canada
    Recruiting
  • Memorial University, Eastern Health
    St. John's, Newfoundland and Labrador, Canada
    Not yet recruiting
  • Dalhousie University; Izaak Walton Killam Health
    Halifax, Nova Scotia, Canada
    Recruiting
  • McMaster University
    Hamilton, Ontario, Canada
    Recruiting
  • Queen's University, Kingston General Hospital Health Sciences Centre
    Kingston, Ontario, Canada
    Recruiting
  • Western University; London Health Sciences Centre, Victoria Hospital
    London, Ontario, Canada
    Recruiting
  • University of Ottawa; The Ottawa Hospital
    Ottawa, Ontario, Canada
    Recruiting
  • Mount Sinai Hospital
    Toronto, Ontario, Canada
    Recruiting
  • Sunnybrook Health Sciences Center
    Toronto, Ontario, Canada
    Recruiting
  • Hopital Maisonneuve Rosemont, CIUSSS de l'est de l'Ile de Montréal
    Montreal, Quebec H1T 2M4, Canada
    Recruiting
  • McGill University, McGill University Health Center, Royal Victoria Hospital
    Montreal, Quebec, Canada
    Recruiting
  • Sir Mortimer B. Davis Jewish General Hospital; McGill University
    Montreal, Quebec, Canada
    Not yet recruiting
  • The Centre Hospitalier Universitaire Sainte-Justine, Université de Montréal
    Montreal, Quebec, Canada
    Recruiting
  • Université Laval, Centre de recherche du CHU de Québec
    Québec, Quebec, Canada
    Recruiting
  • (CIUSSS de l'Estrie-CHUS); Université de Sherbrooke
    Sherbrooke, Quebec, Canada
    Recruiting
  • University of Saskatchewan, Regina General Hospital
    Saskatoon, Saskatchewan, Canada
    Not yet recruiting
08

References and documents

Publications

  • Ninan K, Morfaw F, Murphy KE, Beyene J, McDonald SD. Neonatal and Maternal Outcomes of Lower Versus Standard Doses of Antenatal Corticosteroids for Women at Risk of Preterm Delivery: A Systematic Review of Randomized Controlled Trials. J Obstet Gynaecol Can. 2021 Jan;43(1):74-81. doi: 10.1016/j.jogc.2020.02.127. Epub 2020 Mar 26. PubMed 32660867 ↗

Individual participant data

Plan to share: No — An IPD is planned with trial leaders of another half dose Celestone study.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2023 (actual). Primary completion is estimated for Dec 2026, 41 months after the start.

Of 54 non-industry phase 4 interventional studies under Premature Birth, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 60. This study's planned 41 months is above that.

Counting every sponsor, half of 54 studies reached it within 25 months; a quarter within 13 and three quarters within 60.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 12, 2021
First posted
Nov 9, 2021
StartActual
Jul 20, 2023
Primary completionEst.
Dec 31, 2026
CompletionEst.
Dec 31, 2029
Last update
Jan 7, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 7, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05114096
Collaborators
Hamilton Health Sciences Corporation, Sunnybrook Research Institute, Women's and Children's Hospital, Australia, Canadian Institutes of Health Research (CIHR), Medical Research Future Fund, University of Adelaide
Responsible party
Sponsor
First posted
Nov 9, 2021
Start date
Jul 20, 2023
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2029 (estimated)
Last update
Jan 7, 2026

Study contacts

Sarah D McDonald, MD,MSc,FRCSC
Contact
mcdonals@mcmaster.ca
905-525-9140 ext. 26622
SNACS Coordinating Centre
Contact
SNACS@sunnybrook.ca
Sarah D McDonald, MD,MSc,FRCSC
principal investigator · McMaster University
Kellie Murphy, MD,MSc,FRCSC
principal investigator · University of Toronto

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion